At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03681 SINOMAB BIO-B
Market Closed 12-19 16:08:06
1.480
+0.030
+2.07%
High1.520
Low1.460
Vol1.27M
Open1.460
D1 Closing1.450
Amplitude4.14%
Mkt Cap2.05B
Tradable Cap2.05B
Total Shares1.39B
T/O1.90M
T/O Rate0.09%
Tradable Shares1.39B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Sinomab Bioscience Says IND Application For SM17 Accepted By NMPA CDE
Hong Kong Stock Alert | SINOMAB BIO-B (03681) Surges Over 15% on Significant Clinical Trial and Pipeline Development Progress, First-Half Revenue Reaches RMB 9.802 Million
Hong Kong Stock Movement | SINOMAB BIO-B (03681) Surges Over 11% Intraday Following Strategic Partnership with Sun Yat-sen University Hong Kong Institute for Advanced Study in Biomedical Innovation and R&D
SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.